8-K: Veeva Systems Reports Strong Q2 Fiscal 2026 Results

Veeva Systems Inc. announced robust second-quarter fiscal 2026 results, with total revenues up 17% year over year and all metrics outperforming guidance.

Summary

• Total revenues for the second quarter of fiscal 2026 reached $789.1 million, marking a 17% increase year over year from $676.2 million.
• Subscription services revenues grew 17% year over year to $659.2 million, up from $561.3 million in the prior year.
• GAAP operating income increased 18% year over year to $195.9 million, while non-GAAP operating income rose 26% to $352.6 million.
• GAAP net income was $200.3 million, a 17% increase year over year, and non-GAAP net income grew 25% to $333.4 million.
• Fully diluted net income per share (GAAP) was $1.19, up from $1.04, and non-GAAP fully diluted net income per share was $1.99, up from $1.62.
• Veeva AI is rapidly progressing, with the first agentic AI releases planned for December for CRM and commercial content, and further agents for clinical operations, regulatory, safety, quality, medical, and commercial in 2026, and clinical data in 2027.
• Veeva Vault CRM achieved significant milestones, with over 100 customers live, including two top 20 biopharmas successfully going live in major markets during the quarter, and a seventh top 20 biopharma committing to Vault CRM in August.
• Veeva expanded its Vault CRM Suite with the release of Patient CRM and early customers are now live on Campaign Manager and Service Center.
• Veeva is becoming a foundation for drug development and quality, with another top 20 biopharma selecting Veeva eTMF, Veeva Study Startup, and Veeva Site Connect, and two top 20 biopharmas selecting Veeva Submissions, Submissions Archive, and Registrations.
• All top 20 biopharmas have now selected Veeva eTMF, 19 of the top 20 have selected Veeva QualityDocs, and 18 of the top 20 have selected Veeva Submissions.
• Veeva and IQVIA announced a long-term global partnership and the complete resolution of all pending legal disputes in August 2025, enabling joint customers to use their products and services together efficiently.

Sentiment

Score: 9

Explanation: The filing indicates very strong financial performance, with all metrics outperforming guidance. Strategic initiatives like Veeva AI and Vault CRM are progressing well, securing significant customer adoption, including top biopharmas. The resolution of legal disputes and partnership with IQVIA further enhance the positive outlook. The updated fiscal year guidance is also strong.

Positives

• Total revenues increased by 17% year over year to $789.1 million, exceeding guidance.
• Subscription services revenues grew 17% year over year to $659.2 million.
• GAAP operating income rose 18% year over year to $195.9 million.
• Non-GAAP operating income increased significantly by 26% year over year to $352.6 million.
• GAAP net income grew 17% year over year to $200.3 million.
• Non-GAAP net income increased by 25% year over year to $333.4 million.
• Fully diluted net income per share (GAAP) increased to $1.19 from $1.04.
• Non-GAAP fully diluted net income per share increased to $1.99 from $1.62.
• The business demonstrated broad-based strength and consistent execution, leading to durable, long-term growth.
• Veeva AI is progressing rapidly with a clear strategy, with first agents planned for release in December for CRM and commercial content.
• Veeva Vault CRM has reached over 100 live customers, including two top 20 biopharmas successfully going live in major markets.
• A seventh top 20 biopharma committed to Vault CRM as their commercial foundation in August.
• Expansion of the Vault CRM Suite with Patient CRM, Campaign Manager, and Service Center, with early customers already live.
• All top 20 biopharmas have selected Veeva eTMF, 19 of the top 20 have selected Veeva QualityDocs, and 18 of the top 20 have selected Veeva Submissions, indicating strong market penetration in drug development and quality solutions.
• Resolution of all pending legal disputes and establishment of a long-term global partnership with IQVIA, simplifying product and service usage for joint customers.

Risks

• The company refers to a summary of principal risk factors on pages 32 and 33 in its filing on Form 10-Q for the period ended April 30, 2025, and in subsequent SEC filings, which include issues related to product performance, availability, security, or privacy, competitive factors, customer decisions, life sciences industry developments (regulatory, funding, policy changes), general macroeconomic and geopolitical events (trade policy, inflation, currency, interest rates, conflicts), and challenges in hiring, retaining, and compensating talented employees.

Future Outlook

For the fiscal third quarter ending October 31, 2025, Veeva expects total revenues between $790 million and $793 million, non-GAAP operating income between $348 million and $350 million, and non-GAAP fully diluted net income per share between $1.94 and $1.95. For the full fiscal year ending January 31, 2026, updated guidance projects total revenues between $3,134 million and $3,140 million, non-GAAP operating income of about $1,388 million, and non-GAAP fully diluted net income per share of approximately $7.78.

Management Comments

• CEO Peter Gassner stated, "It's exciting to see our vision of connected software, data, and business consulting for life sciences becoming a reality. I am especially excited about the power of Veeva AI and Veeva Data Cloud to enable transformational change for life sciences from clinical to commercial."
• CFO Brian Van Wagener commented, "We delivered another strong quarter, with results for all metrics outperforming our guidance. The business showed broad-based strength, reflecting our consistent execution and focus on customer success that will enable durable, long-term growth."

Industry Context

Veeva continues to solidify its position as a leading provider of industry cloud solutions for the global life sciences sector. The focus on deep, industry-specific AI, expansion of its Vault CRM Suite, and becoming a foundational platform for drug development and quality aligns with broader industry trends towards digital transformation, data-driven insights, and integrated cloud solutions in pharmaceuticals and biotechnology. The partnership with IQVIA further strengthens its ecosystem, addressing the need for seamless integration across commercial and clinical operations in a complex regulatory environment.

Comparison to Industry Standards

• The filing highlights Veeva's strong market penetration within the top 20 biopharma companies, noting that all have selected Veeva eTMF, 19 of 20 have selected Veeva QualityDocs, and 18 of 20 have selected Veeva Submissions. This indicates a dominant position in critical areas of drug development and quality management.
• No specific comparable companies, projects, or results from competitors were mentioned in the filing to provide a direct assessment against global benchmarks.

Legal Proceedings

• Veeva and IQVIA announced the complete resolution of all pending legal disputes in August 2025, alongside the formation of a long-term global partnership.

Stakeholder Impact

• Shareholders: Strong financial results, outperforming guidance, and positive future outlook are likely to positively impact shareholder value.
• Customers: Continued innovation in Veeva AI, expansion of the Vault CRM Suite, and the partnership with IQVIA are expected to deliver significant, tangible value and simplify product usage for joint customers.
• Employees: The company's growth and strategic advancements suggest a stable and expanding work environment, with stock-based compensation being a notable component of employee remuneration.

Next Steps

• Veeva will host a Q&A conference call on August 27, 2025, at 2:00 p.m. PT.
• The first Veeva AI agents for CRM and commercial content are planned for release in December.
• New Veeva AI agents for clinical operations, regulatory, safety, quality, medical, and commercial are planned for release in 2026.
• Veeva AI agents for clinical data are targeted for release in 2027.

Key Dates

Recommendation

The filing presents exceptionally strong financial results, with all key metrics outperforming guidance and significant year-over-year growth in revenues, operating income, and net income. Strategic initiatives, particularly in AI and the Vault CRM Suite, show robust progress and strong adoption among top biopharma companies. The resolution of legal disputes and a new partnership with IQVIA eliminate uncertainty and open new avenues for growth. The updated fiscal year guidance is also positive, indicating continued momentum. These factors collectively suggest a very favorable outlook for the company's stock.

Keywords

Veeva Systems, Life Sciences Cloud, Q2 Earnings, Fiscal 2026, Subscription Services, Veeva AI, Vault CRM, Drug Development, Clinical Operations, Commercial Solutions, IQVIA Partnership, Biopharma Technology, SEC Filing